At 6.9% CAGR, the Europe Enteral and Parenteral Medical Nutrition Market is projected to be worth US$ 9,054.89 million by 2028, says Business Market Insights

According to Business Market Insights research, the Europe enteral and parenteral medical nutrition market was valued at US$ 6,472.35 million in 2023 and is expected to reach US$ 9,054.89 million by 2028, registering a CAGR of 6.9% from 2023 to 2028. Rise in prevalence of gastrointestinal diseases and increasing cases of malnutrition and premature births are the critical factors attributed to the Europe enteral and parenteral medical nutrition market expansion.        

Crohn’s disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and certain cancers are a few examples of gastrointestinal diseases. Crohn’s disease is a complex, chronic disorder primarily affecting the digestive system. It is the most common disease in Europe. Research conducted by Crohn’s & Colitis UK shows that ~1 in every 123 people in the UK had either Crohn’s disease or ulcerative colitis in 2022, accounting for nearly 0.5 million people living with IBD in the UK. Moreover, short bowel syndrome (SBS) occurs in ~3 per 1 million people yearly. As per the article titled “Understanding Short Bowel Syndrome: Current Status and Future Perspectives," published in 2020, the prevalence of SBS has increased by more than twofold in the last 40 years. 

Patients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They may also face nutritional deterioration due to therapeutic dietary restriction and loss of appetite caused by anorexia or altered nutritional requirement, which can be a result of the disease itself. Thus, medical nutrition is recommended for gastrointestinal disease patients as these patients cannot ingest food. Thus, the enteral and parenteral routes are preferred to provide them with essential nutrients. Enteral feeding refers to food nutrition intake directly through the mouth or through a tube that passes the digestive tract (mouth to stomach/small intestine and then anus). This type of nutrition is preferred to provide treatment support for patients suffering from chronic ailments, such as neurological disorders, gastrointestinal diseases, and inherited metabolic diseases. Some people may not show compatibility toward tube insertion, which makes meeting their calorie and nutrient needs difficult. In such cases, parenteral nutrition is preferred to ensure their bodies remain hydrated and meet the calorie and other nutrient intake required to maintain physical well-being and function. Parenteral nutrition is indicated when patients cannot meet their nutritional needs due to diseases, such as cancer and chronic diseases affecting the gastrointestinal tract. This type of nutrition is the cornerstone of therapy for most patients with severe SBS. Therefore, the elevating prevalence of gastrointestinal diseases drives the growth of the Europe enteral and parenteral medical nutrition market.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with enteral and parenteral feeding systems, and limitations related to catheter placement hampers the Europe Enteral and Parenteral Medical Nutrition Market.  

Based on indication, the Europe enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held 29.9% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 1,936.27 million. It is projected to garner US$ 2,735.77 million by 2028 to expand at 7.2% CAGR during 2023–2028.

Based on nutrition type, the Europe enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 79.6% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 5,150.46 million. It is projected to garner US$ 7,157.90 million by 2028 to expand at 6.8% CAGR during 2023–2028.

Based on form, the Europe enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held 53.2% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 3,443.12 million. It is projected to garner US$ 4,784.56 million by 2028 to expand at 6.8% CAGR during 2023–2028.

Based on product type, the Europe enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held 57.8% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 3,742.36 million. It is projected to garner US$ 5,280.64 million by 2028 to expand at 7.1% CAGR during 2023–2028.

Based on route of administration, the Europe enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held 43.8% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 2,835.23 million. It is projected to garner US$ 3,940.33 million by 2028 to expand at 6.8% CAGR during 2023–2028.

Based on age group, the Europe enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held 39.4% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 2,549.63 million. It is projected to garner US$ 3,577.73 million by 2028 to expand at 7.0% CAGR during 2023–2028.

Based on distribution channel, the Europe enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 41.2% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 2,666.94 million. It is projected to garner US$ 3,688.73 million by 2028 to expand at 6.7% CAGR during 2023–2028.

Based on country, the Europe enteral and parenteral medical nutrition market has been categorized into Germany, the UK, France, Italy, Spain, Poland, Switzerland, Sweden, Belgium, the Netherlands, and the Rest of Europe. Our regional analysis states that Germany captured 22.8% share of Europe Enteral and Parenteral Medical Nutrition Market in 2023. It was assessed at US$ 1,475.32 million in 2023 and is likely to hit US$ 2,092.65 million by 2028, exhibiting a CAGR of 7.2% during the forecast period.      

Key players operating in the Europe enteral and parenteral medical nutrition market are Abbott Laboratories; AYMES International Ltd; B. Braun SE; Baxter International Inc; Charing Cross Scientific AS; Fresenius Kabi AG; Medifood International SA; Nestle SA; Nutricia International BV; and Smartfish AS, among others.  

• November 2021, Abbott Launched Similac 360 Total Care to Support the Immune System, Digestive Health and Brain Development. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby’s health and development, including the developing immune system, digestive system and brain.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com